scanX

Alkem Laboratories

4,765.50
-39.50
(-0.82%)
ann
There are new updates from the company21 hours ago
Viewcross
right
Market Cap
56,978.70 Cr
EPS
150.19
PE Ratio
26.53
Dividend Yield
0.94 %
Industry
Healthcare
52 Week High
6,439.90
52 Week Low
4,491.65
PB Ratio
4.79
Debt to Equity
0.15
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from17 analysts
SELL
Analysts have suggested that investors can sell this stock
Buy
Buy+35.29 %
+35.29 %
Hold
Hold+23.53 %
+23.53 %
Sell
Sell+41.18 %
+41.18 %

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,644.00
#1 3,94,450.67
34.46
#1 49,887.20
12.06
#1 9,648
-18.99
36.89
Divis Laboratories
6,492.50
1,72,355.48
79.22
8,184.00
0.89
1,600
23.05
52.65
Cipla
1,494.30
1,20,681.90
22.95
26,520.70
14.17
4,155
30.28
50.44
Dr Reddys Laboratories
1,321.80
1,10,298.31
19.37
28,905.40
12.36
5,578
21.14
61.31
Torrent Pharmaceuticals
3,192.00
1,08,031.78
56.64
10,785.70
11.59
1,656
10.91
51.94
Zydus Life Science
954.55
96,050.07
20.64
19,831.50
13.82
3,831
-0.19
60.33
Mankind Pharma
2,320.10
95,722.34
48.91
10,615.60
19.57
1,942
-10.91
40.24
Lupin
1,931.10
88,162.62
27.19
20,141.50
#1 19.94
1,936
#1 112.49
43.06
Abbott
31,760.00
67,487.78
47.34
6,097.20
10.80
1,201
27.83
58.17
Aurobindo Pharma
1,094.60
63,574.55
#1 18.61
29,559.20
17.55
3,169
-0.50
35.01

Automatic Screeners on ScanX

Community
Support 1 Breached
Forecast
Actual
Growth Rate
Revenue Growth
9.84 %
Net Income Growth
79.93 %
Cash Flow Change
15.78 %
ROE
58.48 %
ROCE
31.25 %
EBITDA Margin (Avg.)
27.51 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
944
1,244
1,432
1,290
1,252
1,509
1,672
1,507
1,276
1,342
1,889
1,765
1,521
1,686
1,943
1,934
1,882
1,867
2,296
2,210
2,077
2,047
2,398
2,415
2,238
2,778
2,842
2,673
2,504
2,628
3,130
3,086
2,971
3,034
3,503
3,418
3,024
3,152
3,549
3,467
3,290
Expenses
777
1,001
1,127
1,052
993
1,210
1,328
1,214
1,102
1,218
1,405
1,381
1,389
1,455
1,555
1,613
1,619
1,585
1,811
1,729
1,746
1,470
1,762
1,789
1,901
2,139
2,176
2,121
2,162
2,373
2,626
2,442
2,652
2,579
2,751
2,668
2,546
2,423
2,662
2,615
2,753
EBITDA
167
242
306
238
260
299
344
294
174
124
485
384
132
231
388
321
263
282
484
481
331
577
636
626
337
640
666
552
343
255
505
644
319
455
752
750
478
729
887
852
537
Operating Profit %
13 %
16 %
17 %
17 %
14 %
18 %
19 %
18 %
12 %
7 %
24 %
21 %
7 %
12 %
19 %
16 %
13 %
14 %
20 %
21 %
15 %
26 %
25 %
23 %
13 %
22 %
22 %
19 %
13 %
8 %
15 %
20 %
9 %
13 %
20 %
20 %
13 %
20 %
22 %
23 %
12 %
Depreciation
18
21
26
23
24
23
26
26
26
31
35
38
40
43
46
48
57
56
56
60
81
67
70
69
69
71
73
78
83
76
77
78
78
72
74
70
83
81
79
85
113
Interest
17
23
20
19
10
10
12
12
11
13
18
15
10
16
16
15
7
16
18
17
14
17
18
13
11
13
12
11
17
27
25
27
29
30
30
26
27
29
28
36
28
Profit Before Tax
150
211
280
213
225
266
307
255
136
81
432
332
81
172
326
258
199
210
410
405
235
493
548
543
258
556
582
464
243
152
402
539
212
353
648
655
367
619
780
731
396
Tax
19
7
8
23
139
23
19
19
-1
17
105
152
15
35
66
53
28
23
29
15
44
70
66
80
9
76
23
-69
135
20
55
79
144
65
33
51
63
69
78
90
74
Net Profit
132
204
272
190
87
243
288
236
137
64
327
181
66
137
260
205
171
187
381
390
192
423
482
464
249
480
559
533
108
131
348
460
68
288
615
604
305
550
702
641
322
EPS in ₹
11.00
16.82
22.32
15.63
7.25
19.97
23.65
19.52
11.46
5.99
26.82
14.36
5.61
11.39
21.28
16.94
14.00
15.51
31.02
31.95
15.79
35.30
39.48
37.72
20.07
39.15
45.52
43.96
9.00
10.68
27.67
38.03
5.94
23.98
51.90
49.76
24.55
45.60
57.60
52.34
25.57
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
Current Assets
2,338
2,769
2,917
4,013
4,216
5,506
6,923
8,435
8,730
10,412
Capital Work in Progress
111
172
299
381
493
363
393
340
323
159
Investments
61
509
553
444
324
261
333
371
622
484
Other Assets
3,750
3,404
3,919
4,557
4,861
6,413
8,000
10,457
10,129
12,060
Total Liabilities
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
Current Liabilities
2,006
1,538
1,690
2,383
2,218
3,245
3,604
4,805
3,707
3,995
Non Current Liabilities
205
210
296
297
419
392
357
417
615
866
Total Equity
3,085
3,787
4,583
4,985
5,572
6,309
7,558
8,847
9,435
10,714
Reserve & Surplus
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
Share Capital
24
24
24
24
24
24
24
24
24
24
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
39
3
40
0
82
-73
-2
58
42
-208
Investing Activities
-235
205
-294
-351
-318
-737
-995
-1,433
120
-1,011
Operating Activities
326
726
471
266
780
585
1,265
1,111
1,683
1,948
Financing Activities
-52
-927
-138
85
-379
79
-272
380
-1,761
-1,145
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
60.16 %
58.84 %
58.84 %
57.13 %
57.13 %
57.14 %
57.16 %
57.16 %
57.16 %
57.16 %
56.74 %
56.74 %
56.74 %
56.38 %
55.66 %
55.66 %
55.13 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.11 %
8.69 %
9.02 %
10.15 %
9.41 %
DIIs
12.97 %
14.28 %
13.78 %
13.76 %
13.93 %
13.88 %
15.26 %
16.44 %
16.69 %
15.43 %
17.64 %
14.94 %
15.63 %
18.57 %
19.21 %
18.01 %
19.42 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
21.75 %
21.70 %
21.15 %
22.85 %
22.63 %
22.33 %
22.28 %
21.74 %
21.44 %
20.61 %
19.36 %
18.60 %
18.31 %
16.15 %
15.84 %
15.90 %
15.77 %
Others
5.12 %
5.17 %
6.23 %
6.26 %
6.31 %
6.65 %
5.30 %
4.67 %
4.71 %
6.80 %
6.26 %
9.72 %
0.21 %
0.21 %
0.26 %
0.28 %
0.28 %
No of Share Holders
92,594
93,540
87,392
86,881
81,869
84,104
79,721
76,516
73,440
66,790
69,442
65,184
65,830
69,627
74,744
84,038
84,326

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 15 13 16 25 30 34 50 40 0.00
Dividend Yield (%) 0.00 0.75 0.74 0.69 0.9 0.83 1.03 1.01 0.82 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 25 Aug 2025 5,265.65 4,804.60
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 May 2025 5,290.35 5,265.65
14 Feb 2025 DIVIDEND Dividend
₹ 37.00 /share
 14 Feb 2025 5,256.60 4,722.30
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Feb 2025 4,954.15 5,256.60
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2024 5,796.25 5,501.35
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 5,314.35 5,998.65
10 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2024 5,314.35 5,793.15
17 Feb 2024 DIVIDEND Dividend
₹ 35.00 /share
 16 Feb 2024 5,309.25 5,444.15
10 Aug 2023 DIVIDEND Dividend
₹ 10.00 /share
 10 Aug 2023 3,326.30 4,227.25
18 Feb 2023 DIVIDEND Dividend
₹ 25.00 /share
 17 Feb 2023 3,230.05 3,264.35
18 Feb 2023 DIVIDEND Dividend
₹ 15.00 /share
 17 Feb 2023 3,230.05 3,264.35
10 Aug 2022 DIVIDEND Dividend
₹ 4.00 /share
 08 Aug 2022 2,960.40 2,985.40
12 Feb 2022 DIVIDEND Dividend
₹ 30.00 /share
 10 Feb 2022 3,537.95 3,431.45
10 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2021 2,996.15 3,514.65
13 Feb 2021 DIVIDEND Dividend
₹ 25.00 /share
 11 Feb 2021 2,975.90 2,868.65

Announcements

Announcement under Regulation 30 (LODR)-Change in Directorate21 hours ago
Announcement Under Regulation 30 Of SEBI LODR - Regulatory Order5 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 06, 2025
Announcement Under Regulation 30 Of SEBI LODR - Regulatory OrderJun 06, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 29, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Closure of Trading WindowMay 29, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 29, 2025
Corporate Action - Fixes Record Date For [Payment Of Dividend And Cut Off Date For AGMMay 29, 2025
Corporate Action-Board approves DividendMay 29, 2025
Announcement Under Reg 30 - Intimation Of Secretarial AuditorMay 29, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 29, 2025
Results- Please Find Enclosed Herewith The Outcome Of Board Meeting Dated 29Th May 2025. Kindly Take The Same On Record. May 29, 2025
Board Meeting Outcome for Outcome Of BMMay 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held On 29Th May 2025.May 16, 2025
Announcement Under Regulation 30 (LODR) With Respect To A Cyber Security Incident Involving A US Subsidiary Of Enzene Biosciences Limited A Subsidiary Of The Company.May 15, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 23, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 31, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderMar 28, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011Mar 25, 2025
Closure of Trading WindowMar 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 20, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderMar 01, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderMar 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 28, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderFeb 28, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderFeb 28, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderFeb 28, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderFeb 27, 2025
Dislcosure letter under Regulation 11(5) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011.Feb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2025
Announcement Under Regulation 30 Of SEBI LODR- Regulatory OrderFeb 18, 2025

Technical Indicators

RSI(14)
Neutral
36.13
ATR(14)
Less Volatile
120.45
STOCH(9,6)
Neutral
25.56
STOCH RSI(14)
Oversold
13.95
MACD(12,26)
Bearish
-24.76
ADX(14)
Weak Trend
19.89
UO(9)
Bearish
47.52
ROC(12)
Downtrend And Accelerating
-5.72
WillR(14)
Oversold
-88.27
Bearish
3
Neutral
5
Bullish
1

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth
2.77%
139541
0.16%
0.15%
Axis Midcap Direct Plan-Growth
1.29%
-120917
-0.30%
-0.26%
ICICI Prudential Multi Asset Fund Direct-Growth
1.04%
108525
0.06%
0.07%
Bandhan Large & Mid Cap Fund Direct-Growth
0.70%
-75000
-0.52%
-0.53%
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth
0.42%
-73385
-0.18%
-0.17%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
1.85%
48700
0.14%
0.16%
360 ONE Quant Fund Direct - Growth
0.00%
-34883
-2.64%
-2.65%
UTI Healthcare Fund Direct-Growth
1.92%
-23840
-1.23%
-1.07%
Bandhan Midcap Fund Direct-Growth
0.00%
-19850
-0.65%
-0.65%
Mahindra Manulife Multi Cap Fund Direct - Growth
0.71%
-18000
-0.23%
-0.23%
ICICI Prudential Multicap Fund Direct Plan-Growth
1.30%
15094
0.00%
0.00%
Bandhan Multi Cap Fund Direct-Growth
0.68%
-10000
-0.24%
-0.24%
Nippon India Retirement Fund - Wealth Creation Scheme Direct-Growth
0.48%
-10000
-0.18%
-0.16%
Tata Business Cycle Fund Direct - Growth
1.36%
10000
0.14%
1.36%
Kotak Quant Fund Direct - Growth
0.00%
-9667
-0.72%
-2.03%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.00%
-9300
-0.03%
0.00%
Mirae Asset Arbitrage Fund Direct - Growth
0.00%
-7700
-0.13%
-0.15%
Bandhan Large Cap Fund Direct-Growth
0.96%
4436
0.10%
0.11%
Sundaram Mid Cap Fund Direct-Growth
1.60%
4060
-0.08%
-0.02%
SBI Arbitrage Opportunities Fund Direct-Growth
0.00%
-3700
-0.01%
-0.05%
Mirae Asset Healthcare Fund Direct - Growth
2.46%
-3000
-0.07%
-0.03%
LIC MF Balanced Advantage Fund Direct - Growth
0.74%
2808
0.12%
0.14%
Sundaram Large and Mid Cap Fund Direct-Growth
1.93%
2570
-0.02%
0.02%
Sundaram Balanced Advantage Fund Direct-Growth
0.75%
-2100
-0.09%
-0.07%
Bandhan Aggressive Hybrid Fund Direct-Growth
0.87%
-1914
-0.18%
-0.11%

About Alkem Laboratories

Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than 40 international markets, with the United States as its key focus. Alkem is ranked the fifth largest pharmaceutical company in India by domestic sales. The company's product offerings span various therapeutic areas such as anti-infective, cardiology, neurology, and gastroenterology. Alkem has invested in research and development, filing numerous Abbreviated New Drug Applications (ANDAs) with the US FDA. The company has multiple manufacturing facilities in India and abroad, and has expanded through acquisitions and subsidiaries in different countries.
Listing Date
23 Dec, 2015(9 Years, 27 days)
Website
https://www.alkemlabs.com
Chairperson NameBasudeo N Singh
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Fundamental Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104